Introduction to GACP
Good Agricultural and Collection Practices (GACP) form the upstream quality foundation for pharmaceutical cannabis. This module bridges your conventional pharma GMP knowledge with the agricultural discipline that governs your most critical raw material.
What is GACP?
Good Agricultural and Collection Practices (GACP) is a quality framework that governs how medicinal plants are cultivated, harvested, and prepared for use as pharmaceutical starting material. For cannabis, GACP sits directly upstream of GMP — it controls the quality of the material that enters your manufacturing process.
In conventional pharma, your API arrives as a characterized, standardized substance from a qualified supplier. In pharmaceutical cannabis, you are the API manufacturer. The plant itself is the starting material, and GACP is the quality system that governs how you produce it.
In your previous role, API quality was an incoming material problem — supplier qualification, CoA verification, sampling. In pharmaceutical cannabis, API quality is a production problem that starts the moment a seed germinates. GACP is the system that replaces supplier qualification.
Learning objectives
- Understand the purpose and scope of GACP in the pharmaceutical cannabis supply chain
- Identify the key regulatory sources for GACP guidance applicable to medicinal cannabis
- Describe how GACP interfaces with GMP at the starting material boundary
- Apply GACP principles to cultivation, harvest, post-harvest, and documentation activities
- Recognise the critical quality attributes that GACP controls and why they matter for pharmaceutical output
Why GACP matters for pharmaceutical cannabis
Regulatory framework
GACP for pharmaceutical cannabis draws from multiple overlapping regulatory sources. Understanding which guidelines apply — and how they interact — is essential for building a compliant quality system.
The GACP regulatory landscape
Unlike conventional pharmaceutical GMP, where ICH and regional guidance is largely harmonised, GACP for cannabis operates across multiple jurisdictions with different standards. There is currently no single globally harmonised GACP standard for cannabis — but several key documents form the practical foundation.
The GACP–GMP interface: where does one end and the other begin?
This is one of the most important conceptual boundaries in pharmaceutical cannabis. The GACP/GMP boundary is defined by the point at which the plant material is converted into a defined starting material for pharmaceutical manufacture.
| Activity | Governed by | Typical scope |
|---|---|---|
| Cultivation, growth, IPM | GACP | All operations in the grow room or greenhouse, from propagation to harvest |
| Harvesting | GACP | Timing, cutting, handling, contamination prevention at harvest point |
| Drying & curing | GACP / GMP | May fall under either depending on jurisdiction and starting material definition |
| Defined starting material | GMP boundary | Once dried/milled flower or extract is defined as the starting material, GMP applies |
| Extraction, formulation, packaging | GMP | All downstream pharmaceutical manufacturing operations |
You must formally define and document what constitutes your "starting material" for GMP purposes. This decision has major quality system implications and must be agreed with your regulatory authority. The most common definition for dried flower: inspected, dried, and optionally milled cannabis inflorescence meeting defined specifications.
Dual-compliance: the unique challenge
In most jurisdictions, a pharmaceutical cannabis facility faces oversight from two different regulatory bodies — an agricultural authority (governing cultivation) and a pharmaceutical authority (governing manufacturing). Building a quality system that satisfies both simultaneously is one of the most operationally challenging aspects of the role.
Unlike conventional pharma where guidance is stable and mature, GACP cannabis regulations are actively evolving. Assign responsibility for regulatory horizon scanning and build a documented process for incorporating regulatory updates into your QMS. Do not treat this as a one-time compliance exercise.
Starting material & identity
In conventional pharma, your starting material arrives characterised and certified. In pharmaceutical cannabis, you create it. GACP defines how the genetic and botanical identity of your starting material must be established and maintained.
Botanical identity verification
GACP requires that the botanical identity of all starting material is formally established and documented. For cannabis, this means confirming species (Cannabis sativa L.) and, critically, the specific chemovar (chemical variety) being cultivated. This is the foundation of batch-to-batch consistency.
Seed and propagation material controls
Whether starting from seeds or vegetative cuttings, GACP requires documented controls over the origin, identity, and quality of propagation material. This is the equivalent of raw material supplier qualification in conventional pharma.
Think of your chemovar documentation as the equivalent of an API monograph. It defines the botanical species, expected physical characteristics, chemical profile (cannabinoid ratios, terpene profile), and acceptable limits. Every production batch traces back to this reference specification.
Growing medium and substrate controls
The growing substrate is a direct contamination pathway for heavy metals and microbial contamination. GACP requires that all substrates used in cultivation are characterised, approved, and controlled.
For each substrate or soil blend, document: source and supplier, physical characteristics (pH, EC, particle size), microbiological profile, and heavy metal content. Establish approved supplier lists and periodic re-qualification requirements, exactly as you would for excipient suppliers under GMP.
Cultivation conditions
Environmental conditions during cultivation are direct determinants of your final API composition. GACP requires that critical cultivation parameters are defined, controlled, monitored, and documented.
Critical environmental parameters
Unlike a GMP manufacturing environment where conditions primarily affect process reproducibility, cultivation environmental parameters directly affect the chemical composition of the plant. Each parameter is both a process control and an API quality control.
| Parameter | Typical range (flowering) | Quality impact |
|---|---|---|
| Temperature (air) | 22–26°C day / 18–22°C night | High temps accelerate terpene volatilisation and degrade cannabinoids. Stress responses alter cannabinoid profile. |
| Relative humidity | 40–50% RH (late flower) | High RH creates botrytis risk; validated thresholds are a GMP/GACP control boundary. |
| VPD (vapour pressure deficit) | 1.0–1.5 kPa (flower) | Drives transpiration and nutrient uptake. Incorrect VPD causes physiological stress affecting yield and cannabinoid accumulation. |
| Photoperiod | 12h light / 12h dark (flower trigger) | Light cycle initiates and maintains flowering. Interruptions cause re-vegetative growth, destroying the batch. |
| Light intensity (PPFD) | 600–900 µmol/m²/s | Higher PPFD increases cannabinoid biosynthesis up to a saturation point. Must be validated per chemovar. |
| CO₂ concentration | 1000–1500 ppm (enriched) | Elevated CO₂ increases photosynthesis rate and yield. Must be controlled to prevent unsafe workplace levels. |
| Water quality (EC, pH) | pH 5.8–6.5 / EC per growth stage | pH governs nutrient availability; heavy metal content in irrigation water is a direct contamination pathway. |
Define critical process parameters (CPPs) for your cultivation environment, establish validated monitoring systems with calibrated sensors, set alert and action limits, and maintain continuous records. Environmental deviations must be logged, assessed for quality impact, and managed through your CAPA system — exactly as in GMP manufacturing.
Nutrient management
Fertiliser use is a direct contamination pathway for heavy metals. GACP requires that all nutrients and fertilisers are approved, documented, and controlled. Specifically:
- Maintain an approved input list with supplier qualification for all fertilisers and amendments
- Test all nutrient concentrates for heavy metal content before use
- Document nutrient formulations per growth stage and maintain batch records of inputs applied
- Establish a pre-harvest nutrient flush protocol and validate its impact on residual nutrient content
- Retain nutrient use records for traceability to any batch under investigation
Water system controls
Irrigation water quality must meet defined standards for pH, electrical conductivity, microbiological content, and heavy metals. In a pharmaceutical cannabis facility, the water system should be treated with the same rigour as a GMP purified water system: qualified, routinely tested, and documented.
Many cannabis facilities treat water quality as an operational concern rather than a pharmaceutical quality control. Heavy metal contamination via irrigation water is a significant and commonly cited non-conformance in regulatory inspections. Establish water testing against a formal specification with defined limits before first use.
Pest & disease management
Integrated Pest Management (IPM) in pharmaceutical cannabis is fundamentally different from pest control in conventional pharma environments. The threat landscape is biological, the controls are primarily biological, and failures can invalidate entire crops.
In conventional GMP, contamination control focuses on cleanrooms, personnel, and environmental monitoring for particulates and microorganisms. In cannabis cultivation, you are managing a living crop against biological threats — insects, fungi, bacteria — using a toolkit that is mostly biological rather than chemical. This is an entirely different discipline requiring specialist knowledge.
The IPM hierarchy under GACP
GACP requires that pest and disease management follows a prioritised hierarchy that minimises chemical inputs and prioritises prevention and biological control. This is not optional — it is a regulatory requirement, and the rationale is pharmaceutical: chemical pesticide residues in the final product represent a patient safety risk.
Primary threats in pharmaceutical cannabis cultivation
Maintain an IPM logbook as part of your batch record. Record every pest observation (type, severity, location), every monitoring result, every biological or chemical intervention applied, and every residue test result. This documentation is inspected by regulators and forms part of your starting material release dossier.
Harvest & post-harvest handling
Harvest marks the transition from agricultural production to pharmaceutical starting material. Every decision from harvest timing to storage conditions has a direct impact on the quality, potency, and safety of the final product.
Harvest timing and criteria
Unlike a synthetic chemical process where you harvest the product when the reaction is complete, cannabis harvest timing is a judgment call with significant quality implications. GACP requires that harvest criteria are defined, documented, and consistently applied.
Drying and curing
Post-harvest processing is where the majority of quality deterioration occurs if not properly controlled. Drying is a critical step under GACP: improper drying is the leading cause of botrytis contamination in dried flower and directly affects final moisture content, which is a pharmaceutical release parameter.
| Parameter | Target range | Risk if uncontrolled |
|---|---|---|
| Drying temperature | 15–21°C | High temps degrade cannabinoids and terpenes; too low prolongs drying, increasing mould risk |
| Drying humidity | 45–55% RH | Above 60% RH: botrytis and mould risk. Below 35% RH: over-drying, terpene loss |
| Air circulation | Continuous, non-direct | Stagnant air: moisture pockets, uneven drying, mould. Direct airflow: trichome damage |
| Final moisture content | 8–12% (pharmaceutical spec) | Above 12%: microbial growth risk. Below 8%: brittle trichomes, degradation in storage |
| Drying duration | 7–14 days (validated) | Must be validated per chemovar and drying load. Too fast = high moisture; too slow = degradation |
Drying is a critical step that must be validated before routine production. Validation should demonstrate that the process consistently achieves the target moisture content and does not introduce contamination, across the defined range of batch sizes and seasonal temperature/humidity conditions in your facility.
Storage conditions for starting material
Dried cannabis starting material must be stored under defined, monitored, and documented conditions. GACP specifies that storage conditions must protect against deterioration, contamination, and mix-up. Key storage requirements:
- Temperature-controlled environment with continuous monitoring and alarm systems
- Humidity-controlled storage (typically <50% RH) with validated airtight primary packaging
- Light exclusion (cannabinoids degrade under UV) — amber or opaque containers
- Quarantine area for released vs. unreleased material — physical segregation or validated electronic controls
- Re-test period defined and implemented based on stability data
- FIFO (first in, first out) stock rotation procedures documented and audited
Documentation & traceability
Pharmaceutical-grade GACP documentation goes far beyond a cultivation log. It creates an unbroken chain of evidence connecting each gram of finished product back to the seed, the soil, and every environmental event during its growth.
The GACP batch record
The cultivation batch record is the primary GACP document. It is the agricultural equivalent of the pharmaceutical manufacturing batch record — a contemporaneous account of everything that happened to a defined batch of plant material from propagation to starting material release.
Seed-to-sale traceability
Pharmaceutical cannabis is a controlled narcotic substance. Traceability is therefore not only a GACP quality requirement but a legal obligation under narcotic regulations. Every gram must be accounted for from propagation through to final product or destruction.
Personnel qualifications under GACP
GACP requires that all personnel involved in cultivation operations are adequately trained and their qualifications documented. This mirrors GMP personnel requirements but applies to agricultural roles that may be unfamiliar with pharmaceutical documentation culture.
Your cultivation technicians likely come from horticultural or agricultural backgrounds, not pharmaceutical. Invest significant effort in building pharmaceutical documentation culture — contemporaneous record-keeping, "if it's not written down it didn't happen", deviation reporting, and understanding why records matter. This culture gap is the single most common source of GACP non-conformances in inspections.
Knowledge check
Test your understanding of the key GACP principles covered in this module. Select the best answer for each question, then review the feedback before moving to the next.
Summary & key references
Congratulations on completing the GACP module. Here is a consolidated summary of the core principles and the essential reference documents for your continued learning.
Module complete
GACP for pharmaceutical cannabis
Core principles — what to remember
GACP is not agricultural housekeeping — it is pharmaceutical quality management applied to a living production system. Every cultivation decision is an API quality decision.
Define your starting material, agree it with your regulatory authority, and build your quality system around that boundary. Ambiguity here creates compliance risk.
No two harvests are identical. Build specifications and release criteria that accommodate natural biological variation while maintaining pharmaceutical quality. Rigid synthetic pharma tolerances applied to botanical material will generate unnecessary OOS investigations.
The people who grow the plants often come from agricultural backgrounds without pharmaceutical documentation instincts. Training and embedding documentation culture in the cultivation team is as important as the technical training itself.
